Table 1.
Summary of the results of the eight studies evaluating SSAs in gNEN-1 and included in the systematic review.
| Author | Year | Type of study | No. pts | gNEN-1 | Intervention | Schedule | Complete response at 12 m (%) | Follow up (m) | Recurrence (%) |
|---|---|---|---|---|---|---|---|---|---|
| Massironi46 | 2015 | Pros | 12 | Recurrent gNEN-1 | Octreo 30 mg i.m., lanreo 120 mg i.m. | every 28 days For 12 m | 92 | 46.5 | 33 at 20m |
| Khuroo39 | 2010 | Pros | 3 | gNEN-1 | Octreo 20 mg i.m. | every 28 days For 12 m | 100 | 34 | 0 at 34m |
| Grosinski33 | 2008 | Pros | 15 | gNEN-1 | Octreo 20/30 mg i.m. | every 28 days Long-term | 73 | 18 | NA |
| Campana34 | 2008 | Pros | 9 | Multiple gNEN-1 > 5mm | Octreo 30 mg i.m. | every 28 days For 12 m | 100 | 12 | NA |
| Fykse35 | 2004 | Pros | 5 | gNEN-1 | Octreo 20 mg i.m. | every 28 days For 12 m | 80 | 12 | NA |
| Jianu37 | 2011 | Pros | 5 | gNEN-1 | Octreo 20 mg i.m. | every 28 days For 12 m | 80 | 84 | 40 at 60m |
| Thomas18 | 2013 | Retro | 32 | gNEN (G1-2) Type not specified | SSA not further specified | NA | 25 | 39.5 | NA |
| Campana40 | 2016 | Retro | 36 | gNEN (G1-2) Type not specified | Octreo 30/20 mg or lanreo 60/120 mg | every 28 days long term | 76 | NA | NA |
i.m.: intramuscular; gNEN1: gastric neuroendocrine neoplasm type 1; lanreo: lanreotide; octreo: octreotide; pros: prospective; retro: retrospective; SSA: somatostatin analog.